Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. (November 2020)

• Record Type: Journal Article
• Authors: Takahashi, Hidenori; Iwasaki, Yoshinobu; Watanabe, Takayasu; Ichinose, Naoki; Okada, Yasusei; Oiwa, Akito; Kobayashi, Takehiro; Moriya, Mariko; Oda, Toshimi
• Is Part Of: International journal of infectious diseases. Volume 100(2020)
• Page Start: 283
• Page End: 285
• Publication Date: 2020-11
• Subjects: COVID-19 -- SARS-CoV-2 -- viral pneumonia -- favipiravir -- acute respiratory distress syndrome; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2020.08.047
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Case studies of SARS-CoV-2 pneumonia focusing on the effectiveness of favipiravir. Patients were all in a deteriorating, critical, or severe condition. All patients showed a clinical and chest imaging improvement. All patients recovered without subsequent hypoxemia. Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.